Who is sponsoring NCT03684655?

NCT03684655 is sponsored by CellSight Technologies, Inc..

What drugs are being tested in NCT03684655?

Interventions in NCT03684655: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine).

What condition does NCT03684655 study?

NCT03684655 studies HIV Infections.

Is NCT03684655 still recruiting?

NCT03684655 is currently recruiting now. Last updated 24 October 2024.

Last reviewed 2024-10-24 · How we verify

NCT03684655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imaging Immune Activation in HIV by PET-MR

Recruiting now Phase 2 Last updated 24 October 2024

What this trial tests

Phase 2 trial testing [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) in HIV Infections in 30 participants. Currently enrolling.

Timeline

21 September 2018

Primary endpoint
1 October 2025

1 November 2025

Quick facts

Lead sponsor	CellSight Technologies, Inc.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	21 September 2018
Primary completion	1 October 2025
Estimated completion	1 November 2025
Sites	1 location across United States

Drugs / interventions tested

[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

CellSight Technologies, Inc. — full company profile →

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Noninvasive Imaging of Cancer Immunotherapy.
Abousaway O, Rakhshandehroo T, Van den Abbeele AD, Kircher MF, et al · · 2021 · cited 27× · PMID 33391977 · DOI 10.7150/ntno.50860
Molecular Immune Targeted Imaging of Tumor Microenvironment.
Rakhshandehroo T, Smith BR, Glockner HJ, Rashidian M, et al · · 2022 · cited 19× · PMID 35223381 · DOI 10.7150/ntno.66556
Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.
Almutairi WM, Gopaulchan M, Bhaskara R, Zheng QH, et al · · 2026 · PMID 42001384 · DOI 10.1186/s13550-026-01436-6

Verify or expand the search:

Other trials of [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)

Trials testing the same drug.

NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other CellSight Technologies, Inc. trials

Trials by the same sponsor.

NCT06107374 — Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG · Phase 2 · recruiting
NCT06084806 — Test-retest Evaluation of [18F]F-AraG PET · Phase 2 · recruiting
NCT04260256 — A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors · Phase 2 · terminated
NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting
NCT04726215 — Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03684655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CellSight Technologies, Inc.
Last refreshed: 24 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing